 Shares of Apellis Pharmaceuticals Inc. APLS, -1.21 jumped 16.8 in premarket trading on Friday after the company said the Food and Drug Administration accepted an amendment to its drug-approval submission for a geographic atrophy therapy. The FDA is expected to make a decision on the drug by Feb. 26, and the company said the regulator does not plan to hold an advisory committee meeting to discuss the new drug application for pegcetacoplan. 